Showing 1961-1970 of 4063 results for "".
- Opus Genetics Announces 1-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseaseshttps://modernod.com/news/opus-genetics-announces-1-month-clinical-data-from-pediatric-patient-in-phase-12-trial-of-opgx-lca5-gene-therapy-in-inherited-retinal-diseases/2482731/Opus Genetics announced 1-month clinical data from the first pediatric patient treated with its investigational gene therapy, OPGx-LCA5, in an ongoing phase 1/2 open-label trial. The therapy is aimed at treating LCA5-related inherited retinal disease.
- Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-phase-12-data-demonstrates-safety-profile-of-investigational-gene-therapy-botaretigene-sparoparvovec-aav-rpgr-and-sustained-vision-improvement-in-patients-with-xlrp/2481143/MeiraGTx announced the primary results from the phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec (formerly AAV-RPGR) in patients with the inherited retinal disease X-linked retinitis pigmentosa (XLRP) associated with the retinitis pigmentosa GTPase regul
- CMS Issues Final 2021 ASC Payment Rule: 2.4% Increase for Facilitieshttps://modernod.com/news/cms-issues-final-2021-asc-payment-rule-2-4-increase-for-facilities/2478624/On December 2, the Centers for Medicare and Medicaid Services (CMS) issued its final CY 2021 payment rate regulation for hospital outpatient departments (HOPD) and ambulatory surgery centers (ASC). ASC Payme
- At Least 97,000 Children Tested Positive For Coronavirus In Last 2 Weeks Of Julyhttps://modernod.com/news/at-least-97000-children-tested-positive-for-coronavirus-in-last-2-weeks-of-july-at-least-97000-children-tested-positive-for-the-coronavirus-during-the-last-two-weeks-of-july-according-to-a-new-revi/2478145/At least 97,000 children tested positive for the coronavirus during the last two weeks of July, according to a new review of state-level data by the Americ
- Eyenovia Announces Poster Presentation at ASCRS 2022https://modernod.com/news/eyenovia-announces-poster-presentation-at-ascrs-2022/2480776/Eyenovia announced that the company will present an ePoster at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which is being held April 23-26 in Washington, D.C. Details of the ePoster presentation are as follows: <
- Graybug to Present at the 2022 ASCRS Annual Meetinghttps://modernod.com/news/graybug-to-present-at-the-2022-ascrs-annual-meeting/2480770/Graybug Vision announced a platform presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, to be held in Washington, D.C. from April 22-26, 2022. Information is listed below and available on the
- Working With BARDA and FDA on COVID-19 Countermeasureshttps://modernod.com/news/covid-19-working-with-barda-and-fda-on-covid-19-countermeasures/2477443/How can biotech and pharmaceutical companies work with the government in developing and supplying effective diagnostics, treatments and vaccines for COVID-19? What should these companies know? Join Arnold & Porter on Thursday, March 26 from 12–2 pm Eastern Time for an introduction to c
- US Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry AMDhttps://modernod.com/news/us-phase-2-study-published-in-osli-retina-highlights-the-safety-and-efficacy-of-risuteganib-in-patients-with-dry-amd/2479429/Allegro Ophthalmics announced that the results of the company’s US phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina. Entitled
- Allegro Ophthalmics to Present the Results of ALG-1007 Ex-U.S. Phase 2 Clinical Trial for Dry Eye Disease at ASCRShttps://modernod.com/news/allegro-ophthalmics-to-present-the-results-of-alg-1007-ex-u-s-phase-2-clinical-trial-for-dry-eye-disease-at-ascrs/2479379/Allegro Ophthalmics announced that the results of the company’s second ALG-1007 ex-U.S. clinical trial for the treatment of dry eye disease (DED) will be presented during the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS ASOA) an
- Nicox to Receive $2 Million from Ocumension as Milestone Payment Under Zerviate Agreementhttps://modernod.com/news/nicox-to-receive-2-million-from-ocumension-as-milestone-payment-under-zerviate-agreement/2479339/Nicox announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amend